ASMI has commended the TGA for opening up discussion about downscheduling medicines
It also says downscheduling and/or permitting S3 advertising to consumers would help raise awareness of the role of pharmacists.
The TGA is seeking comments from interested parties on the review of the Scheduling Policy Framework and reforms to advertising of Pharmacist-only medicines (Schedule 3 substances). Submissions close April 28.
The current Framework was released in July 2010 and has had minimal review and amendment since this date.
ASMI says it welcomes the range of “positive” options outlined in the consultation document:
- improved governance and transparency
- oversight to fill a policy vacuum and ensure ongoing improvements
- a mechanism to identify candidates for switch
- improved efficiency, transparency and stakeholder engagement
- improved business processes to allow for concurrent scheduling and associated marketing applications with the TGA
- improved focus on benefit and greater examination of risk mitigation techniques
- improvements to advertising controls to allow better access to information about S3 medicines
ASMI also says it welcomes the TGA’s recognition of decisions made by comparable overseas jurisdictions (such as the UK, Ireland, Singapore, Denmark and Canada), and the need to incentivise innovation through down-scheduling, as down-scheduling offers a means for innovative approaches to healthcare.
“ASMI supports scheduling processes that have less focus on risk and more recognition of the benefits to consumers through increased of access to medicine,” the organisation says.
“ASMI is pleased to see that the consultation discusses increased options for mitigating risks, such as pharmacy training, improved labelling, an increased awareness of medicines available to the consumer over-the-counter, and an increased awareness of the role of the pharmacist.
“The consultation document also recognises the synergies possible from streamlining of the processes to switch via the SPF, and the incentive the prospect of more widespread S3 advertising provides to industry.
“This would provide a win for consumers, who will be subsequently be better informed of their treatment options and have a greater understanding of the role of pharmacists in the provision of healthcare for minor ailments and conditions.”
Submissions to the consultation are open until tomorrow, April 28.